Artrya (ASX:AYA) entered a three-year commercial agreement with Northeast Georgia Health System (NGHS) for the clinical use of Salix, the company's cloud platform for the assessment and management of coronary artery disease, according to a Monday filing with the Australian bourse.

Under the deal, Salix will be used for patients with suspected or confirmed coronary artery disease undergoing CT angiography within the Georgia Heart Institute, the filing said.

Salix will be licensed as a SaaS platform with a fixed monthly subscription fee, the filing added.

Assessments performed using Salix's plaque module will generate fee-per-scan revenue, the company said.

The company is preparing the US Food and Drug Administration submission for Salix's coronary flow module.

Shares of the company rose 9% in recent Monday trade.